Kaiser Permanente's national infectious disease leader urges people to adjust their behavior to prevent a new wave of COVID-19 cases from the holidays.
Kaiser Permanente's national infectious disease leader underscores the safety of recently approved COVID-19 vaccines and the importance of avoiding holiday travel.
In a wide-ranging interview Friday with CNBC about COVID-19, Edward M. Ellison, MD, executive medical director and chairman of Southern California Permanente Medical Group, characterized the remdesivir clinical trial as “encouraging.”
Edward M. Ellison, MD, co-CEO of The Permanente Federation, shared on a CNBC broadcast the many ways in which the Permanente Medical Groups have been planning aggressively for a surge of coronavirus patients.
CNBC reported Saturday on the use of telemedicine by health care organizations, and quoted Pat Conolly, MD, The Permanente Federation’s chief information officer.